Literature DB >> 19170639

Binding thermodynamics of the N-terminal peptide of the CCR5 coreceptor to HIV-1 envelope glycoprotein gp120.

Evan T Brower1, Arne Schön, Jeffrey C Klein, Ernesto Freire.   

Abstract

The initial events of HIV-1 cell infection involve the sequential binding of the viral envelope glycoprotein gp120 to the cellular CD4 receptor and the coreceptor, usually CCR5 or CXCR4. Binding to the coreceptor triggers the chain of events that culminates with the entry of the virus into the cell. In this process, the interaction of gp120 with the tyrosine-sulfated N-terminus of CCR5 is critical; however, this interaction has never been characterized at a quantitative or thermodynamic level. Here, we present the first thermodynamic analysis of the interaction of gp120 with the N-terminal peptide of the CCR5 coreceptor. Microcalorimetric titrations demonstrate that measurable binding of S22 peptide, a 22-amino acid tyrosine-sulfated peptide corresponding to the CCR5 N-terminus, requires prior binding of CD4 to gp120. The S22 peptide binds to the gp120-CD4 complex with a binding affinity of 4.5 x 10(5) M(-1) (K(d) = 2.2 microM) in an enthalpically and entropically favorable process. An identical peptide lacking the sulfated tyrosine residues is unable to bind the gp120-CD4 complex. These results indicate that the sulfated tyrosines contribute close to -3.5 kcal/mol to the Gibbs energy of binding. Furthermore, the S22 peptide is a competitive inhibitor of the 17b HIV-1 neutralizing antibody, which is known to bind to the CCR5 coreceptor site in gp120. Together, these results point toward compounds containing sulfated aromatic groups as potential inhibitors of viral entry. In analogy to existing inhibitors that bind to the CCR5 coreceptor directly, these compounds will accomplish the same result by binding to the coreceptor site in gp120.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19170639      PMCID: PMC2700308          DOI: 10.1021/bi8021476

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  38 in total

1.  Estimation of the hydrophobic effect in an antigen-antibody protein-protein interface.

Authors:  E J Sundberg; M Urrutia; B C Braden; J Isern; D Tsuchiya; B A Fields; E L Malchiodi; J Tormo; F P Schwarz; R A Mariuzza
Journal:  Biochemistry       Date:  2000-12-19       Impact factor: 3.162

2.  Structures of HIV-1 gp120 envelope glycoproteins from laboratory-adapted and primary isolates.

Authors:  P D Kwong; R Wyatt; S Majeed; J Robinson; R W Sweet; J Sodroski; W A Hendrickson
Journal:  Structure       Date:  2000-12-15       Impact factor: 5.006

3.  Energetics of the HIV gp120-CD4 binding reaction.

Authors:  D G Myszka; R W Sweet; P Hensley; M Brigham-Burke; P D Kwong; W A Hendrickson; R Wyatt; J Sodroski; M L Doyle
Journal:  Proc Natl Acad Sci U S A       Date:  2000-08-01       Impact factor: 11.205

4.  Structural stability of binding sites: consequences for binding affinity and allosteric effects.

Authors:  I Luque; E Freire
Journal:  Proteins       Date:  2000

5.  HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites.

Authors:  Peter D Kwong; Michael L Doyle; David J Casper; Claudia Cicala; Stephanie A Leavitt; Shahzad Majeed; Tavis D Steenbeke; Miro Venturi; Irwin Chaiken; Michael Fung; Hermann Katinger; Paul W I H Parren; James Robinson; Donald Van Ryk; Liping Wang; Dennis R Burton; Ernesto Freire; Richard Wyatt; Joseph Sodroski; Wayne A Hendrickson; James Arthos
Journal:  Nature       Date:  2002-12-12       Impact factor: 49.962

6.  Mapping the determinants of the CCR5 amino-terminal sulfopeptide interaction with soluble human immunodeficiency virus type 1 gp120-CD4 complexes.

Authors:  E G Cormier; D N Tran; L Yukhayeva; W C Olson; T Dragic
Journal:  J Virol       Date:  2001-06       Impact factor: 5.103

7.  A tyrosine-sulfated peptide based on the N terminus of CCR5 interacts with a CD4-enhanced epitope of the HIV-1 gp120 envelope glycoprotein and inhibits HIV-1 entry.

Authors:  M Farzan; N Vasilieva; C E Schnitzler; S Chung; J Robinson; N P Gerard; C Gerard; H Choe; J Sodroski
Journal:  J Biol Chem       Date:  2000-10-27       Impact factor: 5.157

8.  Structural parameterization of the binding enthalpy of small ligands.

Authors:  Irene Luque; Ernesto Freire
Journal:  Proteins       Date:  2002-11-01

9.  Specific interaction of CCR5 amino-terminal domain peptides containing sulfotyrosines with HIV-1 envelope glycoprotein gp120.

Authors:  E G Cormier; M Persuh; D A Thompson; S W Lin; T P Sakmar; W C Olson; T Dragic
Journal:  Proc Natl Acad Sci U S A       Date:  2000-05-23       Impact factor: 11.205

10.  Tyrosine-sulfated peptides functionally reconstitute a CCR5 variant lacking a critical amino-terminal region.

Authors:  Michael Farzan; Susan Chung; Wenhui Li; Natalya Vasilieva; Paulette L Wright; Christine E Schnitzler; Robb J Marchione; Craig Gerard; Norma P Gerard; Joseph Sodroski; Hyeryun Choe
Journal:  J Biol Chem       Date:  2002-08-14       Impact factor: 5.157

View more
  15 in total

Review 1.  Role of tyrosine-sulfated proteins in retinal structure and function.

Authors:  Y Kanan; M R Al-Ubaidi
Journal:  Exp Eye Res       Date:  2015-04       Impact factor: 3.467

2.  The conformation and orientation of a 27-residue CCR5 peptide in a ternary complex with HIV-1 gp120 and a CD4-mimic peptide.

Authors:  Einat Schnur; Eran Noah; Inbal Ayzenshtat; Hasmik Sargsyan; Tatsuya Inui; Fa-Xiang Ding; Boris Arshava; Yael Sagi; Naama Kessler; Rina Levy; Tali Scherf; Fred Naider; Jacob Anglister
Journal:  J Mol Biol       Date:  2011-07-29       Impact factor: 5.469

3.  Induction of a Tier-1-Like Phenotype in Diverse Tier-2 Isolates by Agents That Guide HIV-1 Env to Perturbation-Sensitive, Nonnative States.

Authors:  Jacklyn Johnson; Yinjie Zhai; Hamid Salimi; Nicole Espy; Noah Eichelberger; Orlando DeLeon; Yunxia O'Malley; Joel Courter; Amos B Smith; Navid Madani; Joseph Sodroski; Hillel Haim
Journal:  J Virol       Date:  2017-07-12       Impact factor: 5.103

4.  Conformational and structural features of HIV-1 gp120 underlying the dual receptor antagonism by cross-reactive neutralizing antibody m18.

Authors:  Syna Kuriakose Gift; Isaac J Zentner; Arne Schön; Karyn McFadden; M Umashankara; Srivats Rajagopal; Mark Contarino; Caitlin Duffy; Joel R Courter; Mei-Yun Zhang; Jonathan M Gershoni; Simon Cocklin; Dimiter S Dimitrov; Amos B Smith; Ernesto Freire; Irwin M Chaiken
Journal:  Biochemistry       Date:  2011-03-18       Impact factor: 3.162

5.  New insights into the mechanisms whereby low molecular weight CCR5 ligands inhibit HIV-1 infection.

Authors:  Javier Garcia-Perez; Patricia Rueda; Isabelle Staropoli; Esther Kellenberger; Jose Alcami; Fernando Arenzana-Seisdedos; Bernard Lagane
Journal:  J Biol Chem       Date:  2010-11-30       Impact factor: 5.157

6.  Isothermal titration calorimetry of membrane proteins - progress and challenges.

Authors:  Krishna Rajarathnam; Jörg Rösgen
Journal:  Biochim Biophys Acta       Date:  2013-06-05

7.  Kinetic mechanism for HIV-1 neutralization by antibody 2G12 entails reversible glycan binding that slows cell entry.

Authors:  Emily J Platt; Michelle M Gomes; David Kabat
Journal:  Proc Natl Acad Sci U S A       Date:  2012-04-30       Impact factor: 11.205

8.  Pattern and temporal sequence of sulfation of CCR5 N-terminal peptides by tyrosylprotein sulfotransferase-2: an assessment of the effects of N-terminal residues.

Authors:  Connie H Jen; Kevin L Moore; Julie A Leary
Journal:  Biochemistry       Date:  2009-06-16       Impact factor: 3.162

9.  Naturally occurring variability in the envelope glycoprotein of HIV-1 and development of cell entry inhibitors.

Authors:  Evan T Brower; Arne Schön; Ernesto Freire
Journal:  Biochemistry       Date:  2010-03-23       Impact factor: 3.162

10.  Two HIV-1 variants resistant to small molecule CCR5 inhibitors differ in how they use CCR5 for entry.

Authors:  Reem Berro; Rogier W Sanders; Min Lu; Per J Klasse; John P Moore
Journal:  PLoS Pathog       Date:  2009-08-14       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.